31st August 2006, 12:00 BST, 07:00 EST: Cambridge, UK… Cambridge Antibody Technology today announces the appointment of Jacqueline Hall to the key management position of Vice President Project Management. 

Jacqueline will be working in the development team, responsible for setting development strategy for CAT projects and delivering projects according to plan. Prior to joining CAT, Jacqueline held the position of Project Leader at GlaxoSmithKline where she was responsible for the strategic development of product candidates from selection through to market launch. She has also held positions at SmithKline Beecham, Pharmaco-LSR and Schering-Plough. 

Jacqueline has a First Class Honours degree in Chemistry from Imperial College of Science and Technology/Birbeck College, London and a Diploma in Clinical Science from the Welsh School of Pharmacy, Cardiff. 

-ENDS- 

Notes to Editors  

Cambridge Antibody Technology (CAT): 

Cambridge Antibody Technology (CAT) is a biopharmaceutical company using its capabilities and technologies in the discovery and development of new and innovative antibody medicines in selected therapeutic areas to bring improvements to seriously ill patients’ lives. CAT is part of the AstraZeneca group of companies. CAT employs around 300 people and is based near Cambridge, UK and in Palo Alto, USA. 

CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company’s strategy to develop a portfolio of antibody-based drugs.

For more information: www.cambridgeantibody.com  

For a high resolution photograph please contact s.yu@northbankcommunications.com  

Contacts: